Key facts
- This page summarizes Jake Simson's Form 4 filing for Janux Therapeutics, Inc. (JANX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2024, 16:30.
Jake Simson - 26 Jun 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- Director
- Issuer ticker
- JANX
- Reported as of
- 26 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2024, 16:30:39 UTC
- Prior SEC filing
- 31 May 2024
- Next SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Maria Dobek, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jake Simson filed Form 4 for Janux Therapeutics, Inc. (JANX) on 28 Jun 2024.
Change
- Previous filing in this sequence was filed on 31 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JANX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,500
- Change %
- Price
- $0.000000
- Shares after
- 2,500
- Date
- 26 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JANX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +8,350
- Change %
- Price
- $0.000000
- Shares after
- 8,350
- Date
- 26 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,350
- Exercise price
- $39.80
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
Footnote F2
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
Footnote F3
The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.